Expanding the Armory: Predicting and Tuning Covalent Warhead Reactivity
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Targeted covalent inhibition is an established approach for increasing the potency and selectivity of potential drug candidates, as well as identifying potent and selective tool compounds for target validation studies. It is evident that identification of reversible recognition elements is essential for selective covalent inhibition, but this must also be achieved with the appropriate level of inherent reactivity of the reactive functionality (or “warhead”). Structural changes that increase or decrease warhead reactivity, guided by methods to predict the effect of those changes, have the potential to tune warhead reactivity and negate issues related to potency and/or toxicity. The half-life to adduct formation with glutathione (GSH t 1/2 ) is a useful assay for measuring the reactivity of cysteine-targeting covalent warheads but is limited to synthesized molecules. In this manuscript we assess the ability of several experimental and computational approaches to predict GSH t 1/2 for a range of cysteine targeting warheads, including a novel method based on p K a . Furthermore, matched molecular pairs analysis has been performed against our internal compound collection, revealing structure–activity relationships between a selection of different covalent warheads. These observations and methods of prediction will be valuable in the design of new covalent inhibitors with desired levels of reactivity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In some cases, covalent inhibitors can be designed to be cleared rapidly after blocking the PPI, which could reduce non-mechanism-based toxicity [37, 139].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [139]
Citations
Cites
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Bochevarov, A. D., Harder, E., Hughes, T. F., Greenwood, J. R., Braden, D. A., Philipp, D. M., Rinaldo, D., Halls, M. D., Zhang, J., & Friesner, R. A. (2013) · International Journal of Quantum Chemistry · doi:10.1002/qua.24481 · Cited by 1,798
Cysteine Proteases and Their Inhibitors
Otto, H.-H., & Schirmeister, T. (1997) · Chemical Reviews · doi:10.1021/cr950025u · Cited by 759
Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state
Patricelli, M. P., Janes, M. R., Li, L.-S., Hansen, R., Peters, U., Kessler, L. V., Chen, Y., Kucharski, J. M., Feng, J., Ely, T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1105 · Cited by 759
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N. (2016) · Science · doi:10.1126/science.aad6204 · Cited by 691
Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
Liu, Q., Sabnis, Y., Zhao, Z., Zhang, T., Buhrlage, S. J., Jones, L. H., & Gray, N. S. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.12.006 · Cited by 652
Jackson, P. A., Widen, J. C., Harki, D. A., & Brummond, K. M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00788 · Cited by 588
Targeted Covalent Inhibitors for Drug Design
Baillie, T. A. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201601091 · Cited by 578
Bauer, R. A. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.05.005 · Cited by 534
Research works printed but not linked: 5
- 2017, Schrödinger Release 2017-2
- 2017, Schrödinger Release 2017-2: Ligprep
- Frisch M. J., 2009, Gaussian 09, Revision E.09
- 2017, Schrödinger Release 2017-2: Macromodel
- 2017, Jaguar, Version 9.5
Cited by
Items 101–200 of 201
Covalent Inhibition of the Histamine H3 Receptor
Wágner, G., Mocking, T. A. M., Kooistra, A. J., Slynko, I., Ábrányi‐Balogh, P., Keserű, G. M., Wijtmans, M., Vischer, H. F., de Esch, I. J. P., & Leurs, R. (2019) · Molecules · doi:10.3390/molecules24244541 · Cited by 10
“Indeed, recent extensions of the diversity in warheads give an opportunity for the fine-tuning of the reactivity [24,25].”
BackgroundStructure-Based Optimization of a Series of Covalent, Cell Active Bfl-1 Inhibitors
Lucas, S. C. C., Blackwell, J. H., Börjesson, U., Hargreaves, D., Milbradt, A. G., Bostock, M. J., Ahmed, S., Beaumont, K. C., Cheung, T., Demanze, S., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01288 · Cited by 10
Size-Dependent Target Engagement of Covalent Probes
Petri, L., Gabizon, R., Ferenczy, G. G., Péczka, N., Egyed, A., Ábrányi‐Balogh, P., Takács, T., & Keserű, G. M. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00017 · Cited by 12
Watanabe, S., Tokunaga, K., Tanaka, Y., Hirose, Y., Mishiro‐Sato, E., Kano, K., Sasaki‐Tabata, K., Kato, Y., Nishida, M., Shindo, N., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c07422 · Cited by 11
Alturki, M. S., & Gomaa, M. S. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118779 · Cited by 9
Natural product-inspired molecules for covalent inhibition of SHP2 tyrosine phosphatase
Liang, W., Krabill, A. D., Gallagher, K. S., Muli, C. S., Qu, Z., Trader, D. J., Zhang, Z., & Dai, M. (2024) · Tetrahedron · doi:10.1016/j.tet.2024.133918 · Cited by 9
Covalent fragment libraries in drug discovery—Design, synthesis, and screening methods
Hocking, B. J. W., Armstrong, A., & Mann, D. J. (2023) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2023.10.003 · Cited by 13
Milgram, B. C., Borrelli, D. R., Brooijmans, N., Henderson, J. A., Hilbert, B. J., Huff, M. R., Ito, T., Jackson, E. L., Jonsson, P., Ladd, B., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02377 · Cited by 9
Structure-based rational design of covalent probes
Holcomb, M., Llanos, M. A., Hansel-Harris, A., & Forli, S. (2025) · Communications Chemistry · doi:10.1038/s42004-025-01606-y · Cited by 10
“78 found that for a series of cysteine-reactive compounds, both the activation barrier (difference in energy between the reactant and transition states) and the formationenergy(differencebetweenreactantandproductstates)werewell correlatedwithreactionrateswithglutathione.”
Graph neural networks for identifying protein-reactive compounds
Gil, V., & Rowley, C. N. (2024) · Digital Discovery · doi:10.1039/d4dd00038b · Cited by 9
Analysis of the ERK Pathway Cysteinome for Targeted Covalent Inhibition of RAF and MEK Kinases
Romany, A., Liu, R., Zhan, S., Clayton, J., & Shen, J. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00014 · Cited by 8
Rodrigues, S. B. D. F., de Araújo, R. S. A., de Mendonça, T. R. D., Mendonça, F. J. B., Zhan, P., & da Silva‐Júnior, E. F. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815179934123010010 · Cited by 8
Danilack, A. D., Dickson, C. J., Soylu, C., Fortunato, M., Rodde, S., Münkler, H., Horn̆ák, V., & Duca, J. S. (2024) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-024-00560-6 · Cited by 9
“HL is relevant for the reaction of acrylamides because the electrons of the nucleophile add to the LUMO orbital of the C 𝛼 =C 𝛽 bond [35, 36, 44, 45].”
InfluentialMeasuring and predicting warhead and residue reactivity
Awoonor‐Williams, E., Kennedy, J., & Rowley, C. N. (2020) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2020.09.001 · Cited by 11
Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
Proj, M., Hrast, M., Knez, D., Bozovičar, K., Grabrijan, K., Meden, A., Gobec, S., & Frlan, R. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00429 · Cited by 10
Emmetiere, F., Ratnayake, R., Schares, H. A. M., Jones, K. F. M., Bevan–Smith, E., Luesch, H., Harki, D. A., & Grenning, A. J. (2021) · Chemistry - A European Journal · doi:10.1002/chem.202100038 · Cited by 8
Kinetic Modeling of Covalent Inhibition: Effects of Rapidly Fluctuating Intermediate States
Ghaby, K., & Roux, B. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c00952 · Cited by 5
Tillmanns, J., Kicuntod, J., Lösing, J., & Marschall, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052823 · Cited by 7
“In city, which then provides close proximity for the covalent interaction (Figure 7A) [111,112].”
BackgroundAllocolchicinoids bearing a Michael acceptor fragment for possible irreversible binding of tubulin
Sazanova, E. S., Gracheva, I. A., Allegro, D., Barbier, P., Combes, S., Svirshchevskaya, E. V., & Fedorov, A. Y. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00060d · Cited by 6
Ramsperger, C. A., Tufts, N. Q., Yadav, A. K., Lessard, J. M., & Stylianou, K. C. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c13945 · Cited by 6
Deep seeking covalent DNA encoded library for novel JAK3 inhibitor discovery
Chen, T., Cai, L., Dong, X., Zhang, L., Cheng, X., Qu, J., Yang, G., Gao, S., Luo, L., Ma, H., et al. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118448 · Cited by 5
Konsue, A., Lamtha, T., Gleeson, D., Jones, D. J. L., Britton, R. G., Pickering, J., Choowongkomon, K., & Gleeson, M. P. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117906 · Cited by 5
Classifying covalent protein binders by their targeted binding site
Bedewy, W. A., Mulawka, J. W., & Adler, M. J. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.130067 · Cited by 6
Computational Methods for Predicting Chemical Reactivity of Covalent Compounds
Zhang, Z., Gao, R., Zhao, M., Zhang, X., Gao, H., Qi, Y., Wang, R., & Li, Y. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c01591 · Cited by 7
Understanding Intrinsic Warhead Reactivity and Cysteine Druggability in Covalent Drug Discovery
Borsari, C., Corfu, A. I., & Conti, P. (2023) · CHIMIA International Journal for Chemistry · doi:10.2533/chimia.2023.349 · Cited by 5
Drugging the undruggable: a computational chemist's view of KRAS G12C
Bodnarchuk, M. S., Cassar, D. J., Kettle, J. G., Robb, G. R., & Ward, R. A. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00055a · Cited by 6
Self-citationCovalent Inhibitors - An Overview of Design Process, Challenges and Future Directions
Mugisa, S., & Murahari, M. (2025) · Current Organic Chemistry · doi:10.2174/0113852728361926250123092017 · Cited by 5
Nyström, H. C., Valaka, A. P., Kalesse, H. A., Håversen, L., Olsson, T., Gunnarsson, A., Schweikart, F., Borén, J., & Grøtli, M. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03536 · Cited by 4
Palisse, A., Cheung, T., Blokhuis, A., Cogswell, T. J., Martins, B. S., Riemens, R., Schellekens, R., Battocchio, G., Jansen, C., Cottee, M. A., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01995 · Cited by 5
Shraga, A., Resnick, E., Gabizon, R., & London, N. (2021) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2021.04.001 · Cited by 10
BIreactive: Expanding the Scope of Reactivity Predictions to Propynamides
Hermann, M. R., Tautermann, C. S., Sieger, P., Grundl, M. A., & Weber, A. (2023) · Pharmaceuticals · doi:10.3390/ph16010116 · Cited by 5
“Mimicking physiological conditions, the half-life of adduct formation in the presence of excess GSH under pseudofirst-order kinetic conditions is often used as a measure of the reactivity for warheads within covalently bound compounds, which can be used to estimate the predictiveness of computational approaches [28,29…”
MethodCovalent Protein Inhibitors via Tyrosine Conjugation with Cyclic Imine Mannich ElectrophilesPreprint
Wang, S., Hadisurya, M., Tao, W. A., Dykhuizen, E. C., & Krusemark, C. J. (2022) · ChemRxiv · doi:10.26434/chemrxiv-2022-tvgn1 · Cited by 7
Meehan, M. C., Scofield, G. E., Stahl, C. E., Wolfe, J. A., Horne, W. S., Liu, P., & Brummond, K. M. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00833 · Cited by 3
Ferenczy, G. G., & Keserű, G. M. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104454 · Cited by 3
Shaping Antimalarials: A Geometry-First Approach to Pf CLK3 Covalent Inhibitors
Brettell, S. B., Bustos, C. F.-G., Sharma, S., Cann, G., Carruthers, L. V., Begen, A., Milligan, G., Clarke, D. J., Tobin, A. B., & Jamieson, A. G. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03342 · Cited by 3
Scholtes, J. F., Alhambra, C., & Carpino, P. A. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2400175 · Cited by 3
“[1,15–18].”
A tunable stimuli-responsive module based on an α-hydroxymethyl-α,β-unsaturated carbonyl scaffold
Shen, R., Zhang, B., Zhao, L., Chang, B., Zhang, F., Chen, Y., & Fang, J. (2025) · Journal of Materials Chemistry B · doi:10.1039/d4tb02818j · Cited by 3
Ghoshal, A., Sears, J. D., Hossain, M. A., Tse, E. G., Howell, S., Burdick, J., Morales, N. L., Martinez, S. A., Law, I., Streblow, Z. J., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01802 · Cited by 3
Kumi, R. O., Issahaku, A. R., Soremekun, O. S., Agoni, C., Olotu, F. A., & Soliman, M. E. S. (2019) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207322666190927143026 · Cited by 3
Lucas, S. C. C., Xu, Y., Hewitt, S. H., Collie, G. W., Fusani, L., Kadamur, G., Hadfield, T. E., Su, N., Truman, C., Demanze, S., et al. (2025) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00582 · Cited by 3
2-Sulfonylpyrimidines: Reactivity Adjustable Agents for Cysteine ArylationPreprint
Pichon, M. M., Drelinkiewicz, D., Lozano, D., Moraru, R., Hayward, L., Jones, M., Mccoy, M., Allstrum-Graves, S., Balourdas, D.-I., Joerger, A. C., et al. (2023) · ChemRxiv · doi:10.26434/chemrxiv-2023-cx8vk · Cited by 3
Ai, Y., Xu, S., Zhang, Y., Liu, Z., & Liu, S. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.07.611751 · Cited by 3
“Some studies have tried to predict the reactivity of covalent inhibitors 35–39 , but reliable methods for predicting the warhead reactivity of TCIs are still lacking.”
Discovery of RMC-6291, a potent, orally bioavailable, covalent RAS(ON) G12C selective inhibitor
Cregg, J., Pota, K., Gill, A. L., & Koltun, E. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00006-1 · Cited by 5
Preparation of ethynylsulfonamides and study of their reactivity with nucleophilic amino acids
Kyoya, T., Ishida, H., Saitoh, T., & Itoh, T. (2025) · Organic & Biomolecular Chemistry · doi:10.1039/d4ob01873g · Cited by 2
Drug development of covalent inhibitors
Dahal, U. P., & Wahlstrom, J. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-817134-9.00009-x · Cited by 2
Molecular Mechanism of Labelling Functional Cysteines by Heterocyclic Thiones
Mihalovits, L. M., Kollár, L., Bajusz, D., Knez, D., Bozovičar, K., Imre, T., Ferenczy, G. G., Gobec, S., & Keserű, G. M. (2023) · ChemPhysChem · doi:10.1002/cphc.202300596 · Cited by 3
Małolepsza, J., Marchwicka, A., Serwa, R. A., Niinivehmas, S. P., Pentikäinen, O. T., Gendaszewska‐Darmach, E., & Błażewska, K. M. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2053525 · Cited by 2
“As electrophilic traps, we chose moieties present in the known drugs with a covalent mechanism of action, targeting cysteines.(6,20) Most synthesised compounds were Michael acceptors but we have also studied chloro- and bromoacetamide fragments (Figure 1A).”
New Chemical Biology Tools for the Histamine Receptor Family
Zheng, Y., Wágner, G., Hauwert, N. J., Ma, X., Vischer, H. F., & Leurs, R. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_360 · Cited by 2
Nucleophilie von Glutathion als Bindeglied zur Reaktivität von Michael‐Akzeptoren
Mayer, R. J., & Ofial, A. R. (2019) · Angewandte Chemie · doi:10.1002/ange.201909803 · Cited by 2
Srinivasan, B. (2023) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2023.08.004 · Cited by 3
Use of new approach methodology for hepatic safety assessment of covalent inhibitor drug candidates
Amberntsson, S., Foster, A. J., Chouhan, B., Wilkinson, S. D., Harlfinger, S., Smith, G., Kettle, J. G., Niedbala, M. J., Kavanagh, S. L., & Williams, D. P. (2025) · Toxicology Research · doi:10.1093/toxres/tfaf054 · Cited by 1
Expanding the landscape of covalent drug discovery: irreversible targeting of non‐cysteine residues
Srinivasan, B., & Taylor, J. B. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70604 · Cited by 2
Therapeutic targeting of CDK12: a medicinal chemistry perspective
Wang, F., Dai, H., Wan, K., & Wang, M. (2026) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2026.118552 · Cited by 1
Chen, Y., Li, J., Delemotte, L., & Mu, Y. (2026) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6c00224 · Cited by 1
DMPK Considerations for the Development of Covalent Drugs: Insights from an IQ Assessment
Dopstadt, J., Behnia, K., Cui, X., Colclough, N., Dowty, M. E., Enoru, J. O., Foti, R., Huth, F., Jacobs, F., Jamwal, R., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00214 · Cited by 1
Self-citationComputational support of structure-based targeted covalent inhibitor design
Abel, R., & Friesner, R. A. (2021) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2021.01.001 · Cited by 2
Ren, Y., Xin, Y., Zhu, R., Zhang, Y., Han, L., & Zhao, Y. (2025) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2025.109017 · Cited by 1
In-silico approaches towards development of model irreversible HIV-1 protease inhibitorsPreprint
Pradhan, R., & Sahu, P. K. (2023) · Research Square · doi:10.21203/rs.3.rs-2547106/v1 · Cited by 1
Liu, R., Vázquez-Montelongo, E. A., Ma, S., & Shen, J. (2023) · ChemRxiv · doi:10.26434/chemrxiv-2023-lh0qp · Cited by 1
Targeting PfCLK3 with Covalent Inhibitors: A Novel Strategy for Malaria TreatmentPreprint
Jamieson, A. G., Brettell, S. B., Janha, O., Begen, A., Cann, G., Olaniyan, N., Sharma, S., Yelland, T., Hole, A. J., Alam, B., et al. (2024) · ChemRxiv · doi:10.26434/chemrxiv-2024-d62kp · Cited by 1
Modeling Covalent Protein-Ligand Interactions
Ward, R. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11519-3
Self-citationDesign, synthesis and trypanocidal activity of cruzain reversible-covalent inhibitors
Cianni, L. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.75.2020.tde-04022020-163539 · Cited by 1
Meden, A., Knez, D., Brazzolotto, X., Modeste, F., Perdih, A., Pišlar, A. H., Zorman, M., Denic, M., Pajk, S., Nachon, F., et al. (2022) · ChemRxiv · doi:10.26434/chemrxiv-2022-msbb4
Conole, D., Cao, F., Ende, C. W. A., Xue, L., Kantesaria, S., Kang, D., Jin, J. H., Owen, D. R., Lohr, L., Schenone, M., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.28.509970
Conole, D., Cao, F., Ende, C. W. A., Xue, L., Kantesaria, S., Kang, D., Jin, J. H., Owen, D. R., Lohr, L., Schenone, M., et al. (2023) · Angewandte Chemie · doi:10.1002/ange.202311190
Approaching novel antibiotic targets using peptidomimetics
Paulussen, F. M. (2023) · doi:10.5463/thesis.473
Ai, Y., Xu, S., Zhang, Y., Liu, Z., & Liu, S. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c03191 · Cited by 3
Optimization and Chemoproteomic Profiling of a Selective, Covalent Bfl-1-Targeting Cellular Tool
Blackwell, J. H., Lucas, S. C. C., Battocchio, G., Börjesson, U., Bostock, M. J., Braybrooke, E. L., Cheung, T., Cottee, M. A., Beaumont, K. C., Gohlke, A., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02581
Rubiano, J. S., Buttery, P. H., Gurard‐Levin, Z. A., Norris-Drouin, J. L., Mather, L. M., Hardy, P. B., Frye, S. V., & James, L. I. (2026) · SLAS DISCOVERY · doi:10.1016/j.slasd.2026.100296 · Cited by 1
Discovery of Ultrapotent Heterodimeric Peptide Ligands Using Library-vs-Library RaPID Selections
Ohno, Y., Vinogradov, A. A., & Suga, H. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.5c23173
Development of small molecules modulating the activity of the nucleoside kinase dCK
Yaala, K. B. (2021) · theses.fr (ABES) · doi:10.70675/749d80bcze0abz4780za87czd786c1617d69
Design of Cyclic Vinyl Sulfones as WRN Covalent Inhibitors from Noncovalent Binders
Caravella, J. A., Toms, A. V., Sitnikov, N., Bartels, F., Svensson, R., Jacques-O’Hagan, S., Borthwick, J., Campos, S., Yin, Y., Zhao, X., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00328
Kim, J., Park, J. H., Kim, T., Jeong, L. S., & Chang, T. (2026) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6c00125
Andrés, C. M. C., de la Lastra, J. M. P., Munguira, E. B., Andrés, C., & Lebeña, E. P. (2026) · Reactions · doi:10.3390/reactions7030050
“…compounds against the DNMT active site, combining quantum mechanical calculations of intrinsic electrophilicity with molecular docking and dynamics simulation of covalent adduct formation [136], fits within the broader resurgence of computational approaches to covalent inhibitor discovery [137].”
BindingDB (2025) · UC San Diego · doi:10.7270/q2vm4hvh
BindingDB Entry 50013902: Discovery of a potent, selective, and covalent ZAP-70 kinase inhibitor.
BindingDB (2022) · UC San Diego · doi:10.7270/q2j96b5b
BindingDB Entry 50013003: Drugging the undruggable: a computational chemist's view of KRAS
BindingDB (2022) · UC San Diego · doi:10.7270/q2db85kh
BindingDB Entry 50007008: Can Cysteine Protease Cross-Class Inhibitors Achieve Selectivity?
BindingDB (2021) · UC San Diego · doi:10.7270/q2k93bt1
BindingDB Entry 50023438: Covalent-Allosteric Inhibitors: Do We Get the Best of Both Worlds?
BindingDB (2026) · UC San Diego · doi:10.7270/q2h136xb
BindingDB (2025) · UC San Diego · doi:10.7270/q2251pw8
BindingDB (2023) · UC San Diego · doi:10.7270/q29p35k4
BindingDB (2026) · UC San Diego · doi:10.7270/q2rv0tkm
BindingDB Entry 50023340: Size-Dependent Target Engagement of Covalent Probes.
BindingDB (2026) · UC San Diego · doi:10.7270/q2cr609x
BindingDB Entry 50023549: Classifying covalent protein binders by their targeted binding site.
BindingDB (2026) · UC San Diego · doi:10.7270/q2xk8mgm
BindingDB (2022) · UC San Diego · doi:10.7270/q2dj5k9t
BindingDB (2026) · UC San Diego · doi:10.7270/q2ws902x
Metadata
- Authors
- Lonsdale, R., Burgess, J., Colclough, N., Davies, N. L., Lenz, E. M., Orton, A. L., & Ward, R. A.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Ward, Richard A.
- Venue
- Journal of Chemical Information and Modeling
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-11-21
- Volume
- 57
- Issue
- 12
- Pages
- 3124-3137
- ISSN
- 1549-9596 (ISSN-L)
- 1549-960X
- OpenAlex
- W2769901316
- Cited by
- 190
- References
- 28
- Citations by year
- 2026: 20 · 2025: 27 · 2024: 25 · 2023: 28 · 2022: 22 · 2021: 20 · 2020: 23 · 2019: 18 · 2018: 7
- FWCI
- 9.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Chemical Information and Modeling (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- covalent warheads, matched molecular pairs, structure-activity relationship, covalent inhibitors
- MeSH terms
- Acrylamides, Cysteine, Glutathione, Humans, Models, Molecular, Structure-Activity Relationship, Drug Discovery, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.